1st International Bladder Cancer Update
In conjunction with the Medical College of Wisconsin (MCW), Carden Jennings Publishing Co.,Ltd. (CJP) proposes to develop a live conference on the topic of bladdercancer. This conference will encompass expert lectures, interactive discussions, a panel roundtable, debates, and case reports. It will be physician-led, multi-supported, and designed for urologists, medical oncologists, and other healthcare professionals involved in the treatment of bladder cancer. This conference will be the 1st annual International Bladder Cancer Update (IBCU1), and is being held at The Westin Riverfront at Beaver Creek, CO from January 24, 2017. This activity will be a Sunshine-exempt, CME-accredited educational program. As such, it will meet the following requirements: (1) the provider and program is accredited, (2) no direct payments are allowed between CME supporters and physician faculty, and (3) CME supporters have no role in directing, suggesting, or implementing how the proceeds of the grant are used by the CME provider.
Program Goal
The goal of this educational program is to equip urologists, medical oncologists, and other healthcare professionals involved in the treatment of bladder cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of bladder cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating bladder cancer patients, and to give them a chance to discuss the issues with peers and experts.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
Learning Objectives
The following are the learning objectives in CME format for this program. Upon completion of
this program, participants will be able to effectively address:
- new clinical practice guidelines
- Current best practices in prevention and screening of bladder cancer
- Updates on the use of biomarkers
- Promising therapies
- Issues and economic concerns in the tratment of low and high risk patients
- The sequencing of available therapies in 2016
Available Credit
- 5.75 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 5.75 Hours of ParticipationHours of Participation credit.

Facebook
X
LinkedIn
Forward